57, df = 90, P = 0.012). As shown in table 2, in comparison analysis of mental disorder prevalence in studied groups based on cut-off point, general symptom index (GSI) has been considered as 0.7. 88.4% of HIV/AIDS substance abusers, 75.5% of non-HIV/AIDS substance abusers, and 53.0% of their healthy matched group that showed mental disorder symptoms click here are significant based on ��2 (��2 = 13.87, df = 2, P < 0.001). Table 2 Mental disorders in the 3 groups of substance abusers with and without HIV/AIDS and healthy matched group Table 3 shows the number distribution (Mean �� SD) and results of ANOVA of subscales of the SCL-90-R test, representing diverse mental aspects of the psychopathology of HIV/AIDS and non-HIV/AIDS groups, and their healthy matched group.
Table 3 Results of Analysis of Variance (ANOVA) of psychopathology dimensions in the 3 groups As seen in table 3, there is a significant difference between these 3 groups in all psychopathological dimensions (i.e. the ratio of calculated F by free grades is 2 and 134) and all subscales of SCL-90-R test (P < 0.05). Table 4 also presents the results of two-by-two mean comparison of groups using Gabriel post-hoc test, the power of which is good particularly in discriminating unequal groups with different sample sizes.32 Table 4 Results of two-by-two mean comparison of groups by Gabriel post-hoc test in different dimensions of psychopathology Gabriel post-hoc test showed that HIV/AIDS substance abusers report significantly more symptoms and show a more acute mental status in all dimensions compared to their healthy matched group.
This is also true in all psychopathological dimensions, except hostility and paranoid ideation, compared to non-HIV/AIDS substance abusers. There was also a significant difference in depression, anxiety, psychoticism, GSI, and PSDI between substance abusers without HIV/AIDS and the healthy matched group. Figure 1 by T standard score for all subscales of SCL-90-R is the best method to demonstrate the difference and order of mental disorder symptoms, and distribution of psychopathological profile of the 3 groups in this study. Figure 1 Comparison of distribution of psychopathological profile of the 3 groups GSI: Global severity index; PST: Positive symptom total; PSDI: Positive symptom distress index Discussion This research aimed to compare psychopathological dimensions in substance abusers with and without HIV/AIDS and their matched group.
Finding a clear discrimination between and a sample of mental disorder symptoms in these groups is an important step in promotion of medical outcomes and prognosis of multiple chronic, mental, and medical diseases Carfilzomib (addiction with HIV/AIDS). Data showed that the population of substance abusers with HIV/AIDS report significantly higher rates of drug injection history (P = 0.041) and imprisonment (P < 0.012) compared to substance abusers without this infection.